CD19 and non-Hodgkin lymphoma: 2, 3 During clinical trials with the CD19-CD3 specific bsAb blinatumomab, objective clinical responses were observed in most patients suffering from CD19-expressing non-Hodgkin's lymphoma and acute lymphoblastic leukemia.4, 5 In these studies the blinatumomab was delivered to patients by continuous intravenous infusion over several weeks.